Log in

NASDAQ:ISRIsoRay Stock Price, Forecast & News

$0.57
+0.01 (+1.78 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.56
Now: $0.57
$0.59
50-Day Range
$0.56
MA: $0.66
$0.75
52-Week Range
$0.29
Now: $0.57
$1.06
Volume159,426 shs
Average Volume542,246 shs
Market Capitalization$38.74 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is headquartered in Richland, Washington.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.62 out of 5 stars


Industry, Sector and Symbol

Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ISR
CUSIPN/A
CIKN/A
Phone509-375-1202

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees43
Market Cap$38.74 million
Next Earnings Date9/22/2020 (Estimated)
OptionableNot Optionable

Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for ISR and its competitors with MarketBeat's FREE daily newsletter.

IsoRay (NASDAQ:ISR) Frequently Asked Questions

How has IsoRay's stock been impacted by COVID-19 (Coronavirus)?

IsoRay's stock was trading at $0.6706 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ISR stock has decreased by 14.6% and is now trading at $0.5727. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IsoRay?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IsoRay.

When is IsoRay's next earnings date?

IsoRay is scheduled to release its next quarterly earnings announcement on Tuesday, September 22nd 2020. View our earnings forecast for IsoRay.

How were IsoRay's earnings last quarter?

IsoRay, Inc. (NASDAQ:ISR) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.01). The business had revenue of $2.88 million for the quarter, compared to analysts' expectations of $2.76 million. View IsoRay's earnings history.

Has IsoRay been receiving favorable news coverage?

News headlines about ISR stock have trended negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IsoRay earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about IsoRay.

Who are some of IsoRay's key competitors?

What other stocks do shareholders of IsoRay own?

Who are IsoRay's key executives?

IsoRay's management team includes the following people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 58)
  • Mr. Michael L. Krachon, VP of Sales & Marketing (Age 49)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 54)
  • Mr. Jonathan R. Hunt, CFO & Co-Principal Financial Officer (Age 53)
  • Ms. Jennifer Streeter, Interim COO & VP of HR (Age 50)

What is IsoRay's stock symbol?

IsoRay trades on the NASDAQ under the ticker symbol "ISR."

How do I buy shares of IsoRay?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IsoRay's stock price today?

One share of ISR stock can currently be purchased for approximately $0.57.

How big of a company is IsoRay?

IsoRay has a market capitalization of $38.74 million. IsoRay employs 43 workers across the globe.

What is IsoRay's official website?

The official website for IsoRay is www.isoray.com.

How can I contact IsoRay?

The company can be reached via phone at 509-375-1202.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.